BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 27470087)

  • 21. Presence of enthesopathy in patients with primary Sjogren's syndrome: ultrasonographic study of a local cohort.
    Sag S; Sag MS; Tekeoglu I; Kamanlı A; Nas K
    J Med Ultrason (2001); 2018 Jan; 45(1):121-127. PubMed ID: 28646319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients.
    Seror R; Gottenberg JE; Devauchelle-Pensec V; Dubost JJ; Le Guern V; Hayem G; Fauchais AL; Goeb V; Hachulla E; Hatron PY; Larroche C; Morel J; Pedriger A; Puechal X; Rist S; Saraux A; Sene D; Sibilia J; Vittecoq O; Zarnitsky C; Labetoulle M; Ravaud P; Mariette X
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1358-64. PubMed ID: 23436737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.
    Dumusc A; Ng WF; James K; Griffiths B; Price E; Pease C; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Gupta M; McLaren J; Cooper A; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman S
    Swiss Med Wkly; 2018; 148():w14588. PubMed ID: 29442344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of the EULAR Sjögren syndrome disease activity index in Japanese children: a retrospective multicenter cohort study.
    Iwata N; Tomiita M; Kobayashi I; Inoue Y; Nonaka Y; Okamoto N; Umebayashi H; Hara R; Ito Y; Sato Y; Mori M
    Pediatr Rheumatol Online J; 2020 Sep; 18(1):73. PubMed ID: 32943063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of abatacept for the treatment of patients with primary Sjögren's syndrome.
    Machado AC; Dos Santos LC; Fidelix T; Lekwitch I; Soares SB; Gasparini AF; Augusto JV; Junior NC; Trevisani VFM
    Clin Rheumatol; 2020 Jan; 39(1):243-248. PubMed ID: 31420813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.
    Demarchi J; Papasidero S; Medina MA; Klajn D; Chaparro Del Moral R; Rillo O; Martiré V; Crespo G; Secco A; Catalan Pellet A; Amitrano C; Crow C; Asnal C; Pucci P; Caeiro F; Benzanquen N; Pirola JP; Mayer M; Zazzetti F; Velez S; Barreira J; Tamborenea N; Santiago L; Raiti L
    Clin Rheumatol; 2017 Nov; 36(11):2455-2460. PubMed ID: 28913747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry).
    Ramos-Casals M; Brito-Zerón P; Solans R; Camps MT; Casanovas A; Sopeña B; Díaz-López B; Rascón FJ; Qanneta R; Fraile G; Pérez-Alvarez R; Callejas JL; Ripoll M; Pinilla B; Akasbi M; Fonseca E; Canora J; Nadal ME; de la Red G; Fernández-Regal I; Jiménez-Heredia I; Bosch JA; Ayala MD; Morera-Morales L; Maure B; Mera A; Ramentol M; Retamozo S; Kostov B; ;
    Rheumatology (Oxford); 2014 Feb; 53(2):321-31. PubMed ID: 24162151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
    Gottenberg JE; Cinquetti G; Larroche C; Combe B; Hachulla E; Meyer O; Pertuiset E; Kaplanski G; Chiche L; Berthelot JM; Gombert B; Goupille P; Marcelli C; Feuillet S; Leone J; Sibilia J; Zarnitsky C; Carli P; Rist S; Gaudin P; Salliot C; Piperno M; Deplas A; Breban M; Lequerre T; Richette P; Ghiringhelli C; Hamidou M; Ravaud P; Mariette X;
    Ann Rheum Dis; 2013 Jun; 72(6):1026-31. PubMed ID: 23264337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren's syndrome Endocrinopathy) trial.
    Tsuboi H; Matsumoto I; Hagiwara S; Hirota T; Takahashi H; Ebe H; Yokosawa M; Yagishita M; Takahashi H; Kurata I; Ohyama A; Honda F; Asashima H; Miki H; Umeda N; Kondo Y; Hirata S; Saito K; Tanaka Y; Horai Y; Nakamura H; Kawakami A; Sumida T
    Mod Rheumatol; 2016 Nov; 26(6):891-899. PubMed ID: 27459020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative analysis of the efficacy and safety of herbal decoction CheReCunJin alone and combined with hydroxychloroquine for treating primary Sjögren's syndrome: A randomized controlled trial.
    Shao Q; Jin L; Li C; Wang J; Wang M; Wang Q; Wu B
    Explore (NY); 2022; 18(4):416-422. PubMed ID: 34417112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of systemic activity of pediatric primary Sjögren's syndrome by EULAR Sjögren's syndrome disease activity index (ESSDAI).
    Kobayashi I; Okura Y; Ueki M; Tozawa Y; Takezaki S; Yamada M; Ariga T
    Mod Rheumatol; 2019 Jan; 29(1):130-133. PubMed ID: 29529894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polyarthritis in primary Sjögren's syndrome represents a distinct subset with less pronounced B cell proliferation a Dutch cohort with long-term follow-up.
    ter Borg EJ; Kelder JC
    Clin Rheumatol; 2016 Mar; 35(3):649-55. PubMed ID: 26791875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcultural adaptation of the "EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)" into Brazilian Portuguese.
    Serrano EV; Valim V; Miyamoto ST; Giovelli RA; Paganotti MA; Cadê NV
    Rev Bras Reumatol; 2013; 53(6):483-93. PubMed ID: 24477727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20).
    Devauchelle-Pensec V; Pennec Y; Morvan J; Pers JO; Daridon C; Jousse-Joulin S; Roudaut A; Jamin C; Renaudineau Y; Roué IQ; Cochener B; Youinou P; Saraux A
    Arthritis Rheum; 2007 Mar; 57(2):310-7. PubMed ID: 17330280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
    Delli K; Haacke EA; Kroese FG; Pollard RP; Ihrler S; van der Vegt B; Vissink A; Bootsma H; Spijkervet FK
    Ann Rheum Dis; 2016 Nov; 75(11):1933-1938. PubMed ID: 26757748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome measures for primary Sjögren's syndrome: a comprehensive review.
    Seror R; Theander E; Bootsma H; Bowman SJ; Tzioufas A; Gottenberg JE; Ramos-Casals M; Dörner T; Ravaud P; Mariette X; Vitali C
    J Autoimmun; 2014 Jun; 51():51-6. PubMed ID: 24411404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe intestinal dysbiosis is prevalent in primary Sjögren's syndrome and is associated with systemic disease activity.
    Mandl T; Marsal J; Olsson P; Ohlsson B; Andréasson K
    Arthritis Res Ther; 2017 Oct; 19(1):237. PubMed ID: 29065905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab in central nervous system manifestations of patients with primary Sjögren's syndrome: results from the AIR registry.
    Mekinian A; Ravaud P; Larroche C; Hachulla E; Gombert B; Blanchard-Delaunay C; Cantagrel A; Fain O; Sibilia J; Gottenberg JE; Mariette X;
    Clin Exp Rheumatol; 2012; 30(2):208-12. PubMed ID: 22341206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren's syndrome adults from a defined population.
    Akiyama M; Sasaki T; Kaneko Y; Yasuoka H; Suzuki K; Yamaoka K; Takeuchi T
    Clin Exp Rheumatol; 2018; 36 Suppl 112(3):157-164. PubMed ID: 29465360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry.
    Oni C; Mitchell S; James K; Ng WF; Griffiths B; Hindmarsh V; Price E; Pease CT; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Hunter J; Gupta M; McLaren J; Cooper A; Regan M; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman SJ;
    Rheumatology (Oxford); 2016 Mar; 55(3):544-52. PubMed ID: 26510429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.